INNOVIVA, INC. (INVA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 47.06M USD | Liabilities, Current |
| Cash and equivalents | 570.39M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 38.97M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $47.06M | $570.39M | (m) | (m) | $38.97M | (m) |
| 2026-03-31 | (m) | $36.56M | $603.09M | (m) | (m) | $38.84M | (m) |
| 2025-12-31 | (m) | $49.70M | $550.94M | (m) | (m) | $39.17M | (m) |
| 2025-09-30 | (m) | $48.47M | $476.51M | (m) | (m) | $38.36M | (m) |
| 2025-06-30 | (m) | $246.56M | $397.53M | (m) | (m) | $49.00M | (m) |
| 2025-03-31 | (m) | $234.75M | $319.09M | (m) | (m) | $41.48M | (m) |
| 2024-12-31 | (m) | $236.08M | $304.96M | (m) | (m) | $33.73M | (m) |
| 2024-09-30 | (m) | $223.75M | $260.63M | (m) | (m) | $34.24M | (m) |
| 2024-06-30 | (m) | $28.21M | $217.00M | (m) | (m) | $36.66M | (m) |
| 2024-03-31 | (m) | $29.88M | $178.36M | (m) | (m) | $37.44M | (m) |
| 2023-12-31 | (m) | $38.13M | $193.51M | (m) | (m) | $40.74M | (m) |
| 2023-09-30 | (m) | $36.18M | $180.00M | (m) | (m) | $40.52M | (m) |
| 2023-06-30 | (m) | $39.40M | $173.03M | (m) | (m) | $46.85M | (m) |
| 2023-03-31 | (m) | $38.14M | $144.05M | (m) | (m) | $49.65M | (m) |
| 2022-12-31 | (m) | $134.97M | $291.05M | (m) | (m) | $55.90M | (m) |
| 2022-09-30 | (m) | $163.88M | $300.79M | $282.00K | (m) | $70.81M | (m) |
| 2022-06-30 | (m) | $125.91M | $283.58M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $109.23M | $216.80M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $5.81M | $201.53M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $3.13M | $135.12M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.37M | $43.27M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.80M | $282.89M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $6.11M | $246.49M | $0.00 | (m) | (m) | (m) |
| 2020-09-30 | (m) | $3.90M | $479.19M | $0.00 | (m) | (m) | (m) |
| 2020-06-30 | (m) | $5.41M | $413.15M | $4.00M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $2.80M | $351.98M | $31.97M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.37M | $278.10M | $72.75M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $3.33M | $172.95M | $124.25M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $7.47M | $141.95M | $107.71M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.81M | $65.15M | $127.03M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $5.70M | $62.42M | $52.49M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $4.30M | $48.62M | $6.87M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $6.78M | $87.23M | $20.32M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $4.07M | $27.14M | $29.32M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $34.74M | $73.34M | $55.74M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $32.88M | $138.42M | $29.77M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $27.11M | $127.63M | $7.99M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $20.47M | $159.81M | $10.00M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $20.05M | $118.02M | $32.42M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $14.92M | $93.19M | $55.77M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $14.63M | $112.94M | $40.92M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $10.62M | $151.78M | $16.41M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $13.49M | $159.18M | $28.10M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $11.28M | $78.75M | $127.45M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $12.21M | $149.58M | $79.68M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $10.98M | $141.19M | $109.95M | (m) | (m) | (m) |
| 2014-12-31 | $240.50M | $13.76M | $96.80M | $143.70M | $0.00 | $0.00 | 17.48× |
| 2014-09-30 | $263.11M | $36.10M | $119.58M | $143.54M | $0.00 | $0.00 | 7.29× |
| 2014-06-30 | $334.48M | $49.99M | $208.05M | $126.42M | $0.00 | $0.00 | 6.69× |
| 2014-03-31 | $370.93M | $44.14M | $125.28M | $245.65M | $3.00K | $11.01M | 8.40× |
| 2013-12-31 | $465.32M | $84.40M | $143.51M | $321.62M | $199.00K | $10.41M | 5.51× |
| 2013-09-30 | (m) | $38.66M | $171.89M | $334.26M | (m) | $9.04M | (m) |
| 2013-06-30 | (m) | $38.65M | $199.24M | $243.77M | (m) | $8.24M | (m) |
| 2013-03-31 | (m) | $29.46M | $266.07M | $192.99M | (m) | $8.05M | (m) |
| 2012-12-31 | (m) | $29.97M | $94.85M | $153.64M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $27.09M | $112.23M | $161.21M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $25.78M | $161.10M | $134.39M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $25.57M | $14.31M | $185.85M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $45.50M | $44.78M | $196.14M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $39.81M | $62.74M | $202.43M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $35.19M | $90.66M | $193.23M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $147.87M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $40.05M | $163.33M | $146.30M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $63.10M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $69.72M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $47.54M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $92.28M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |